-
Russian tanker set to deliver oil to crisis-hit Cuba
-
Iran fires missiles across Middle East as Trump threatens oil hub
-
Indonesia summons Google, Meta for 'not complying' with teen social media ban: minister
-
Wembanyama at the double as Spurs beat Bulls
-
Australia investigates tech giants over social media ban breaches
-
Hindu devotional clubbing sways India's youth
-
Oil slips, stocks rise as report says Trump willing to end war
-
Mind games: How football stars are fuelling chess boom
-
Indonesia trims meals programme: what next?
-
'A very big deal': Canadian astronaut reflects on historic Moon mission
-
US pro table tennis league blasts niche sport into spotlight
-
Trump threatens to destroy Iran oil island despite claims of talks
-
NASA begins countdown to April 1 Moon launch
-
NBA Bulls fire Ivey after anti-LGBTQ comments
-
Australian regulator probes Facebook, YouTube over teen social media ban
-
Iraq coach shielding players from war ahead of World Cup bid
-
Undav rescues Germany late in Ghana friendly
-
Messi to start for Argentina in World Cup send-off: Scaloni
-
Oil rises on Trump's Iran threats, stocks mixed
-
After pope's remark, White House defends praying for US troops
-
Powell probe leaves US Fed leadership change in limbo
-
Celine Dion announces comeback following health struggle
-
'Is it Kafka?' US judge baffled by new Pentagon press policy
-
Cubans ready for Russian oil but some say not enough
-
Teen Suryavanshi shines as Rajasthan hammer Chennai in IPL
-
Stock market winners and losers one month into US-Israel war on Iran
-
Hodgson says surprise return to management is only for short-term
-
What could Trump achieve by threatening Iran's Kharg Island?
-
India declares victory over Maoist insurgency
-
Germany's Merz pushes return of Syrians as he hosts leader Sharaa
-
G7 ministers pledge 'necessary measures' to ensure stable energy market
-
Cardiff City lose compensation case over Emiliano Sala death
-
Several French far-right mayors take down EU flags
-
Air Canada CEO to retire after row over English-only condolence message
-
Oil rises on Trump's Iran threats, stocks take cue on talks
-
Syrian leader pledges to work with Germany on migration, recovery
-
AI agent future is coming, OpenClaw creator tells AFP
-
Cardiff lose 122 mn euro compensation case over Emiliano Sala death
-
Tuchel defends Rice and Saka after England withdrawals
-
G7 ministers tackle economic fallout of Mideast war
-
Tottenham close in on De Zerbi as next boss - reports
-
Kenya's former NY marathon champion Korir gets 5-year doping ban
-
Lukaku says 'could never turn back on Napoli' after treatment row
-
Syrian leader visits Germany to talk war, recovery, refugees
-
Renault says developing ground-based military drone
-
Iran hangs two 'political prisoners' from banned opposition: activists
-
Russia expels UK diplomat on spying allegations
-
Premier League fans back call to scrap VAR
-
Italy hoping to scale World Cup 'Everest' ahead of Bosnia play-off showdown
-
Japan's cherry blossom season dazzles locals and tourists
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Schubert--BTB